Jay H Traverse

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction
    Jay H Traverse
    Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN University of Minnesota School of Medicine, Minneapolis, MN 55407, USA
    Am Heart J 158:356-63. 2009
  2. ncbi request reprint Effect of K+ATP channel and adenosine receptor blockade during rest and exercise in congestive heart failure
    Jay H Traverse
    Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Circ Res 100:1643-9. 2007
  3. doi request reprint Cell therapy for acute myocardial infarction--where do we go from here?
    Jay H Traverse
    Cardiovascular Division, Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, University of Minnesota Medical School, Minneapolis, MN, USA
    J Cardiovasc Transl Res 1:64-70. 2008
  4. ncbi request reprint Measurement of myocardial free radical production during exercise using EPR spectroscopy
    Jay H Traverse
    Cardiovascular Division, University of Minnesota Medical School, Mayo Mail Code 508, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Am J Physiol Heart Circ Physiol 290:H2453-8. 2006
  5. doi request reprint Using biomaterials to improve the efficacy of cell therapy following acute myocardial infarction
    Jay H Traverse
    Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN 55407, USA
    J Cardiovasc Transl Res 5:67-72. 2012
  6. doi request reprint Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardia
    Jay H Traverse
    The Minneapolis Heart Institute at Abbott Northwestern Hospital, MN 55407, USA
    Am Heart J 162:671-7. 2011
  7. pmc Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction
    Jay H Traverse
    Minneapolis Heart Institute, Abbott Northwestern Hospital, MN 55407, USA
    Am Heart J 160:428-34. 2010
  8. ncbi request reprint Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts
    Yingjie Chen
    Department of Medicine, Univ of Minnesota Medical School, Minneapolis, MN 55455, USA
    Am J Physiol Heart Circ Physiol 289:H2212-9. 2005
  9. ncbi request reprint Increased superoxide production causes coronary endothelial dysfunction and depressed oxygen consumption in the failing heart
    Yingjie Chen
    Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
    Am J Physiol Heart Circ Physiol 288:H133-41. 2005
  10. ncbi request reprint Nitric oxide modulates myocardial oxygen consumption in the failing heart
    Yingjie Chen
    Department of Medicine, Division of Cardiology, University of Minnesota Medical School, Minneapolis 55455, USA
    Circulation 106:273-9. 2002

Detail Information

Publications30

  1. pmc Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction
    Jay H Traverse
    Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN University of Minnesota School of Medicine, Minneapolis, MN 55407, USA
    Am Heart J 158:356-63. 2009
    ..This study will provide further insight into the clinical feasibility and appropriate timing of autologous BMMNC therapy in high-risk patients after AMI and percutaneous coronary intervention...
  2. ncbi request reprint Effect of K+ATP channel and adenosine receptor blockade during rest and exercise in congestive heart failure
    Jay H Traverse
    Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Circ Res 100:1643-9. 2007
    ..These findings demonstrate that coronary K(+)(ATP) channel activity contribute to the regulation of resting MBF in CHF, and that endogenous adenosine may act to inhibit MVO(2) in the failing heart...
  3. doi request reprint Cell therapy for acute myocardial infarction--where do we go from here?
    Jay H Traverse
    Cardiovascular Division, Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, University of Minnesota Medical School, Minneapolis, MN, USA
    J Cardiovasc Transl Res 1:64-70. 2008
    ..We believe that future cell therapy trials should attempt to incorporate these important issues in designing upcoming clinical trials in order for the field to move forward...
  4. ncbi request reprint Measurement of myocardial free radical production during exercise using EPR spectroscopy
    Jay H Traverse
    Cardiovascular Division, University of Minnesota Medical School, Mayo Mail Code 508, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Am J Physiol Heart Circ Physiol 290:H2453-8. 2006
    ..Thus, in contrast to skeletal muscle, submaximal treadmill exercise did not result in detectable free radical production by the heart...
  5. doi request reprint Using biomaterials to improve the efficacy of cell therapy following acute myocardial infarction
    Jay H Traverse
    Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN 55407, USA
    J Cardiovasc Transl Res 5:67-72. 2012
    ..This review discusses the potential use of biologically based ECM surrogates in the clinical setting following STEMI...
  6. doi request reprint Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardia
    Jay H Traverse
    The Minneapolis Heart Institute at Abbott Northwestern Hospital, MN 55407, USA
    Am Heart J 162:671-7. 2011
    ....
  7. pmc Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction
    Jay H Traverse
    Minneapolis Heart Institute, Abbott Northwestern Hospital, MN 55407, USA
    Am Heart J 160:428-34. 2010
    ..However, results from trials performed in the United States have not yet been presented...
  8. ncbi request reprint Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts
    Yingjie Chen
    Department of Medicine, Univ of Minnesota Medical School, Minneapolis, MN 55455, USA
    Am J Physiol Heart Circ Physiol 289:H2212-9. 2005
    ..Decreased DDAH activity and DDAH-2 protein expression may cause accumulation of endogenous inhibitors of endothelial NOS, thereby contributing to endothelial dysfunction in the failing heart...
  9. ncbi request reprint Increased superoxide production causes coronary endothelial dysfunction and depressed oxygen consumption in the failing heart
    Yingjie Chen
    Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
    Am J Physiol Heart Circ Physiol 288:H133-41. 2005
    ..Cytosolic Cu/Zn-containing SOD was unchanged. Both increased O(2)(-). production and decreased vascular O(2)(-). scavenging ability by EC-SOD could have contributed to endothelial dysfunction in the failing hearts...
  10. ncbi request reprint Nitric oxide modulates myocardial oxygen consumption in the failing heart
    Yingjie Chen
    Department of Medicine, Division of Cardiology, University of Minnesota Medical School, Minneapolis 55455, USA
    Circulation 106:273-9. 2002
    ..Although endothelial NOS responses are depressed in congestive heart failure (CHF), inducible NOS (iNOS) may be expressed in failing myocardium...
  11. ncbi request reprint Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure
    Yingjie Chen
    Department of Medicine, Division of Cardiology, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Am J Physiol Heart Circ Physiol 284:H1513-20. 2003
    ..Furthermore, Western blotting showed decreased PDE5 protein expression in myocardium from failing hearts. These findings demonstrate that PDE5 contributes little to regulation of coronary hemodynamics in CHF...
  12. pmc Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial
    Jay H Traverse
    Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota, USA
    JAMA 308:2380-9. 2012
    ....
  13. ncbi request reprint Inhibition of NO production increases myocardial blood flow and oxygen consumption in congestive heart failure
    Jay H Traverse
    Division of Cardiology, Department of Medicine, University of Minnesota Medical School, Minneapolis 55455, USA
    Am J Physiol Heart Circ Physiol 282:H2278-83. 2002
    ..05). Although L-NNA significantly increased LV systolic pressure, similar increases in pressure produced by phenylephrine did not increase MVO(2). The findings suggest that NO exerts tonic inhibition on respiration in the failing heart...
  14. pmc Oxidative stress regulates left ventricular PDE5 expression in the failing heart
    Zhongbing Lu
    Cardiovascular Division, University of Minnesota, Minneapolis, MN 55455, USA
    Circulation 121:1474-83. 2010
    ..The purpose of this study is to test the hypothesis that oxidative stress causes increased PDE5 expression in cardiac myocytes and that increased PDE5 contributes to the development of CHF...
  15. pmc Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial
    Jay H Traverse
    Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, Minnesota, USA
    JAMA 306:2110-9. 2011
    ..However, because a substantial number of patients may not present for early cell delivery, the efficacy of autologous BMC delivery 2 to 3 weeks post-MI warrants investigation...
  16. doi request reprint Long-term follow-up of patients undergoing postconditioning during ST-elevation myocardial infarction
    Santiago Garcia
    Minneapolis VA Medical Center, Minneapolis, MN, USA
    J Cardiovasc Transl Res 4:92-8. 2011
    ..The beneficial effects of postconditioning on cardiac function persist beyond 3 years...
  17. ncbi request reprint ET-A receptor activity restrains coronary blood flow in the failing heart
    Mingxiao Hou
    Department of Medicine, University of Minnesota Health Sciences Center, Minneapolis, USA
    J Cardiovasc Pharmacol 43:764-9. 2004
    ..Thus, although ET-A receptor blockade caused a modest increase in coronary flow, this did not result in an increase of MVO2, implying that ET-A-mediated coronary vasoconstriction did not limit oxygen uptake by the failing heart...
  18. ncbi request reprint A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction
    Timothy D Henry
    Minneapolis Heart Institute Foundation, 920 E 28th St, Ste 40, Minneapolis, MN 55407, USA
    Circulation 116:721-8. 2007
    ..In the United States, transfer times are consistently long; therefore, many believe a transfer for PCI strategy for STEMI is not practical...
  19. doi request reprint Long-term survival in patients with refractory angina
    Timothy D Henry
    Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, 920 East 28th Street, Suite 100, Minneapolis, MN 55407, USA
    Eur Heart J 34:2683-8. 2013
    ..Despite limited data regarding the natural history and predictors of adverse outcome, these patients have been considered at high risk for early mortality...
  20. ncbi request reprint ST-elevation myocardial infarction diagnosed after hospital admission
    Ross F Garberich
    Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN
    Circulation 129:1225-32. 2014
    ..Limited data exist regarding treatment times and outcomes for patients who develop STEMI after hospital admission...
  21. pmc Preinfarction angina reduces infarct size in ST-elevation myocardial infarction treated with percutaneous coronary intervention
    Ronald Reiter
    Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN 55407, USA
    Circ Cardiovasc Interv 6:52-8. 2013
    ..However, the benefits of preinfarction angina in the setting of primary percutaneous coronary intervention with stenting is inconclusive because of the greater achievement of infarct artery patency and speed of reperfusion...
  22. pmc Circadian dependence of infarct size and left ventricular function after ST elevation myocardial infarction
    Ronald Reiter
    Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN 55407, USA
    Circ Res 110:105-10. 2012
    ..In rodents, infarct size after ischemia/reperfusion exhibits a circadian dependence on the time of coronary occlusion. It is not known if a similar circadian dependence of infarct size occurs in humans...
  23. doi request reprint Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality
    Benjamin Williams
    Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota 55407, USA
    Catheter Cardiovasc Interv 75:886-91. 2010
    ..To determine the contemporary prevalence of and mortality in patients with coronary artery disease (CAD) not amenable to revascularization...
  24. ncbi request reprint Comparison of safety and efficacy of sirolimus-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction
    Marc C Newell
    Department of Internal Medicine, Abbott Northwestern Hospital, Minneapolis, USA
    Am J Cardiol 97:1299-302. 2006
    ..01) and the need for target vessel revascularization (p = 0.02). In conclusion, SESs are safe and effective in STEMI at 6 months...
  25. pmc A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction
    Joshua M Hare
    Department of Medicine, Cardiovascular Division and the Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, Florida 33136, USA
    J Am Coll Cardiol 54:2277-86. 2009
    ..Our aim was to investigate the safety and efficacy of intravenous allogeneic human mesenchymal stem cells (hMSCs) in patients with myocardial infarction (MI)...
  26. ncbi request reprint Clinical, angiographic, and interventional follow-up of patients with aortic-saphenous vein graft connectors
    Jay H Traverse
    Minneapolis Cardiology Associates, Minneapolis Heart Institute at Abbott Northwestern Hospital, 920 East 28th Street, Suite 300, Minneapolis, Minn 55407, USA
    Circulation 108:452-6. 2003
    ....
  27. ncbi request reprint Emerging therapies for refractory angina
    Daniel Satran
    Division of Cardiovascular Disease, Minneapolis Heart Institute Foundation Abbott Northwestern Hospital, University of Minnesota, USA
    Minn Med 91:36-9. 2008
    ....
  28. ncbi request reprint Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial
    Douglas W Losordo
    Feinberg Cardiovascular Research Institute, and Department of Medicine, Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital, Chicago, IL 60611, USA
    Circulation 115:3165-72. 2007
    ..Preclinical studies have indicated that human CD34+ stem cells induce neovascularization in ischemic myocardium, which enhances perfusion and function...
  29. ncbi request reprint CPCs as treatment for chronic total coronary artery occlusions
    Jay H Traverse
    Circ Res 98:e1. 2006
  30. ncbi request reprint The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Invasive Cardiol 15:611-6. 2003
    ..Bivalirudin appeared safe and provided effective anticoagulation during PCI. These data, and extensive experience with bivalirudin in PCI, support its use in high-risk patients with HIT requiring PCI...